FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 29 filers reported holding FUSION PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,458 | -44.3% | 8,253 | 0.0% | 0.00% | – |
| Q2 2023 | $38,541 | +23.9% | 8,253 | 0.0% | 0.00% | – |
| Q1 2023 | $31,114 | +19.7% | 8,253 | 0.0% | 0.00% | – |
| Q4 2022 | $25,997 | +4.0% | 8,253 | 0.0% | 0.00% | – |
| Q3 2022 | $25,000 | +25.0% | 8,253 | 0.0% | 0.00% | – |
| Q2 2022 | $20,000 | -68.8% | 8,253 | 0.0% | 0.00% | – |
| Q1 2022 | $64,000 | +60.0% | 8,253 | -13.6% | 0.00% | – |
| Q4 2021 | $40,000 | -98.8% | 9,553 | -97.7% | 0.00% | – |
| Q3 2021 | $3,281,000 | -13.6% | 414,256 | -11.9% | 0.00% | – |
| Q2 2021 | $3,799,000 | -56.1% | 470,303 | -41.8% | 0.00% | – |
| Q1 2021 | $8,657,000 | -11.3% | 807,536 | -2.8% | 0.00% | – |
| Q4 2020 | $9,760,000 | +76.6% | 830,737 | +80.6% | 0.00% | – |
| Q3 2020 | $5,528,000 | -30.2% | 459,918 | +1.5% | 0.00% | – |
| Q2 2020 | $7,918,000 | – | 453,191 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $9,543,342 | 3.52% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $7,664,303 | 2.68% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,982 | $4,058,553 | 1.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,354,258 | $3,521,071 | 0.64% |
| Avidity Partners Management LP | 5,781,850 | $15,032,810 | 0.60% |
| Eagle Health Investments LP | 579,769 | $1,507,399 | 0.33% |
| Perceptive Advisors | 2,751,395 | $7,153,627 | 0.24% |
| Ghost Tree Capital, LLC | 243,287 | $632,546 | 0.21% |
| Sio Capital Management, LLC | 246,036 | $639,694 | 0.20% |
| Artal Group S.A. | 1,725,000 | $4,485 | 0.19% |